From January 1, 2022 to March 13, 2022, the company has repurchased 860,800 shares, representing 0.14% for CNY 9.03 million. With this, the company has completed the repurchase of 5,000,000 shares, representing 0.81% for CNY 59.98 million under the buyback announced on March 15, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.85 CNY | -0.82% | -1.22% | -24.22% |
05-20 | Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Dividend for the Year 2023 | CI |
05-08 | US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A | MT |
1st Jan change | Capi. | |
---|---|---|
-24.22% | 410M | |
+15.91% | 42.02B | |
+22.40% | 21.66B | |
+18.18% | 15.09B | |
+16.12% | 14.21B | |
+45.12% | 12.37B | |
-0.05% | 6.79B | |
-9.58% | 6.59B | |
+14.13% | 5.56B | |
+4.17% | 4.64B |
- Stock Market
- Equities
- 002082 Stock
- News Wanbangde Pharmaceutical Holding Group Co., Ltd.
- Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021.